KAIST study opens a new avenue for treating intractable brain tumors
Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune “brakes” exploited by…
Polymer-based immunotherapies enhance tumor targeting and immune activation
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less…
Combination therapy may help overcome barrier in early-stage prostate cancer treatment
A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy…
UCSF team uncovers breakthrough immunotherapy for colon cancer liver metastases
Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest…